Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study

Leukemia

Volumn 29, Issue 7, 2015, Pages 1602-1604

  Goede, V ^a   Fischer, K ^a   Engelke, A ^a   Schlag, R ^b   Lepretre, S ^c   Montero, L F C ^d   Montillo, M ^e   Fegan, C ^f   Asikanius, E ^g   Humphrey, K ^h   Fingerle Rowson, G ^g   Hallek, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Hematology and Oncology Practice   (Germany)

^c CENTRE HENRI BECQUEREL   (France)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CHLORAMBUCIL; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CREATININE CLEARANCE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CANCER STAGING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84937023635     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.14     Document Type: Letter

References (14)

1. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011; 152: 295-306
2. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010; 115: 4393-4402
3. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013; 12: 2031-2042
4. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370: 1101-1110
5. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456
6. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995; 43: 130-137
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41
8. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174
9. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-Term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980
10. Hillmen P, Robak T, Janssens A, Govindbabu K, Grosicki S, Mayer J, et al. Ofatumumab+chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood. 2013; 122: 528
11. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-Arm, phase 2 study. Lancet Oncol. 2014; 15: 1090-1099
12. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-223
13. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007
14. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014; 15: 48-58